POSB342 Time Until Definitive Deterioration (TUDD) in Patient Reported Outcomes (PROS) in a Phase 3 Trial for Ripretinib in 4L Patients with Gastrointestinal Stromal Tumour (GIST)

Article2022

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

Patrick Schöffski, Suzanne George, Michael C. Heinrich, John Zalcberg, Sebastian Bauer, Hans Gelderblom, César Serrano, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Claus Becker, Kelvin Shi, Julie Meade, Rodrigo Ruiz‐Soto, Jean Yves Blay, Margaret von Mehren

Article2020

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

Jean Yves Blay, César Serrano, Michael C. Heinrich, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Julie Meade, Kelvin Shi, Rodrigo Ruiz‐Soto, Suzanne George, Margaret von Mehren

Article2021

Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.

John Zalcberg, Michael C. Heinrich, Suzanne George, Sebastian Bauer, Patrick Schöffski, César Serrano, Robin L. Jones, Hans Gelderblom, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Neeta Somaiah, Julie Nicole Meade, V. Reichert, Kelvin Shi, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Margaret von Mehren, Jean Yves Blay

Article2020

Quality of life (QoL) and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.

Michael C. Heinrich, Suzanne George, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, C Pardo Serrano, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Claus Becker, Julie Nicole Meade, Rodrigo Ruiz‐Soto, Margaret von Mehren, Jean Yves Blay

Article2024

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

Michael C. Heinrich, Robin L. Jones, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Brittany L. Siontis, David Goldstein, Kjetil Boye, César Sánchez, Neeltje Steeghs, Piotr Rutkowski, Mihaela Druta, César Serrano, Neeta Somaiah, Ping Chi, William M. Reichmann, Kam Sprott,

Discussion(0)

Related publications